The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG).
D. Walterhouse
No relevant relationships to disclose
A. S. Pappo
No relevant relationships to disclose
J. L. Meza
No relevant relationships to disclose
J. C. Breneman
Research Funding - Children's Oncology Group
A. A. Hayes-Jordan
No relevant relationships to disclose
D. Parham
No relevant relationships to disclose
T. P. Cripe
No relevant relationships to disclose
W. H. Meyer
No relevant relationships to disclose
D. S. Hawkins
No relevant relationships to disclose